Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07170046

Predictive Value of CEA and ctDNA in Lung Cancer Recurrence

The study aims to investigate the predictive value of CEA levels for postoperative recurrence in the highly sensitive CEA lung cancer patients and to explore whether the dynamic changes of postoperative CEA and MRD in this population are related.This study was carried out to accurately predict the recurrence time, save the time and cost of changing the intervention strategy, and provide more personalized treatment for patients.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Lung Carcinoma Lung Diseases Lung Neoplasms Neoplasms Neoplasms by Site Respiratory Tract Diseases Respiratory Tract Neoplasms Thoracic Neoplasms

Age range

15 year–100 year

Sex eligibility

All sexes

Study type

Observational

About this study

This study will collect two groups of cohorts: prospective and retrospective.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Preoperative CEA > 5mg/l
  • MRD testing was conducted before the operation
  • The primary lesion was resected through surgery
  • There should be at least two CEA and MRD follow-up tests within 2 years after the operation
  • Postoperative pathology confirmed it as a malignant lung tumor

Exclusion criteria

  • Those without available imaging records
  • Patients with a history of malignant tumors within the past five years
  • Patients with secondary lung cancer

Treatment and study plan

Primary outcomes

  1. Postoperative tumor recurrence or progression

    Time frame: 2 years

    If the tumor recurs or progresses within 2 years, it will be marked as 1. If not, it will be marked as 0.

Sponsors and collaborators

Lead sponsor

Guangdong Provincial People's Hospital

Other

Registry information

Official study title

Predictive Value of CEA and ctDNA for Postoperative Recurrence in Patients With High CEA Sensitivity Lung Cancer

Important dates

Study start
2025
Primary completion
2027
Study completion
2027
First posted
Sep 12, 2025
Registry last updated
Sep 12, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.